Biotech firm Recepticon receives DKK 31 m cash injection  

2006.01.20
A venture capital syndicate and Østjysk Innovation have put DKK 31 m into Århus based Recepticon to enable continued development of a promising therapeutic substance

A venture capital syndicate and Østjysk Innovation have put DKK 31 m (USD 5 m) into Århus based Recepticon to enable continued development of a promising therapeutic substance.

"We can now make preparations for the first clinical trials in humans, which I expect will start in 2007," says Professor Anders Nykær of Aarhus University, who with Professor Thomas Willnow from Germany's Max Delbrück Center for Molecular Medicine in Berlin, founded Recepticon in 2001.

Besides Østjysk Innovation, the syndicated companies putting money into Recepticon comprise Dansk Erhvervsinvesting, Incuba Venture, Vecata and the Swedish venture company Innovationskapital.

Recepticon is aiming to develop a therapeutic substance which can protect humans from potentially serious side-effect risks of antibiotic treatment with aminoglycosides like gentamycin. These side effects can include damage to the kidney and ear, which are costly from both the human suffering and economic perspectives. The news was reported in daily financial newspaper Børsen.

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×